UK markets close in 7 hours 8 minutes
  • FTSE 100

    6,640.72
    -11.24 (-0.17%)
     
  • FTSE 250

    21,091.91
    -106.21 (-0.50%)
     
  • AIM

    1,184.18
    -7.68 (-0.64%)
     
  • GBP/EUR

    1.1481
    -0.0016 (-0.14%)
     
  • GBP/USD

    1.3935
    -0.0078 (-0.55%)
     
  • BTC-GBP

    33,203.24
    -2,990.72 (-8.26%)
     
  • CMC Crypto 200

    923.28
    -9.85 (-1.06%)
     
  • S&P 500

    3,829.34
    -96.09 (-2.45%)
     
  • DOW

    31,402.01
    -559.85 (-1.75%)
     
  • CRUDE OIL

    63.03
    -0.50 (-0.79%)
     
  • GOLD FUTURES

    1,767.20
    -8.20 (-0.46%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,849.99
    -29.34 (-0.21%)
     
  • CAC 40

    5,753.76
    -30.13 (-0.52%)
     

Cognito Therapeutics Appoints Mark Day, Ph.D., as Chief Business Officer

·3-min read

Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders including Alzheimer’s disease, announced today the appointment of Mark Day, Ph.D., as Chief Business Officer. In this role, Dr. Day will drive business development and partnership activities at Cognito in conjunction with the Cognito leadership team.

Dr. Day brings more than 21 years of business, corporate, research and development strategy expertise to Cognito. He has evaluated over 300 programs, resulting in a uniquely broad knowledge base and network in the pharmaceutical industry. He has successfully led product licensing, strategic alliances, mergers and acquisitions and product development programs with major pharmaceutical and biotechnology companies in neuroscience and rare disease indications.

Prior to joining Cognito, Dr. Day was Vice President, head of the McQuade Centre for Research and Development & Early-Stage Life Science Investment (MSRD) at Otsuka U.S., where he evaluated numerous early-stage central nervous system (CNS) programs. Prior to Otsuka, he was the Chief Executive Officer at Bioasis Technologies, Inc., a biopharmaceutical company developing novel therapies for CNS disorders. He has also held senior roles at Alexion Pharmaceuticals, Wyeth and Abbott.

"As Cognito continues to build momentum following our recent FDA Breakthrough Device Designation for our lead product for the treatment of Alzheimer’s, we are excited to have Mark join us to further strengthen our leadership team," said Brent Vaughan, Chief Executive Officer of Cognito Therapeutics. "His depth of knowledge leading therapeutic programs in neuroscience and CNS disorders will be invaluable, as we expand the development of Cognito’s pipeline of digital therapeutics to effect disease modification in a broader range of neurodegenerative diseases."

"Cognito’s digital therapeutic device has the potential to transform the treatment landscape across a number of indications by addressing the etiology of neurodegenerative diseases, beginning with Alzheimer’s," said Mark Day, Ph.D., Chief Business Officer, Cognito Therapeutics. "I look forward to working with Brent and the rest of the executive leadership team while leveraging pharmaceutical and biotech development efforts to bring Cognito’s next-generation digital therapeutic devices to patients suffering from neurodegenerative disorders and other chronic diseases."

Dr. Day earned a B.Sc. (Hons) in Biological Psychology and a Ph.D. in Neuroscience from Cardiff University. He completed his post doctorate studies in systems level neuroscience at The University of Edinburgh. Dr. Day has authored more than 100 peer-reviewed scientific papers in leading medical journals on translational medicine, impulsivity, stroke, cognitive dysfunction in neurological and psychiatric illness such as Alzheimer’s disease and ADHD, including first authorships in Nature, Science, Nature Neuroscience, Neuroimaging and Proceedings of the Royal Society.

About Cognito Therapeutics

Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics that have shown drug-like effects to treat neurodegenerative disorders including Alzheimer’s disease. The company’s licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive, neurostimulation therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases. The company is based in Boston and San Francisco. For more information, please visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005241/en/

Contacts

Media Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com